{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:57:49Z","timestamp":1794880669505,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Baxdrostat is a selective inhibitor of aldosterone synthase designed for the treatment of disorders associated with elevated aldosterone. This study evaluated the safety, pharmacokinetics, and pharmacodynamics of multiple ascending doses of baxdrostat in healthy volunteers. Subjects were randomized to receive oral baxdrostat (0.5, 1.5, 2.5, or 5.0\u2009mg) or placebo once daily for 10 days and were placed on either a low-salt or normal-salt diet for the duration of the study. Blood samples were collected before and after dosing on days 1 and 10 to characterize pharmacokinetics and pharmacodynamics. Safety was assessed by adverse events, physical examinations, electrocardiograms, orthostatic vital signs, and clinical laboratory evaluations. Fifty-four subjects completed the study. There were no deaths or serious adverse events, and all treatment-emergent adverse events in subjects receiving baxdrostat were mild in severity. Plasma levels of baxdrostat increased proportionally with ascending doses, with peak concentrations observed within 4\u2009h after dosing and a mean half-life of 26 to 31\u2009h. A dose-dependent reduction of plasma aldosterone occurred with baxdrostat doses \u22651.5\u2009mg, regardless of diet. Decreases in plasma aldosterone were sustained, with levels reduced by approximately 51 to 73% on day 10. Baxdrostat had no meaningful impact on plasma cortisol levels and resulted in mild dose-dependent decreases in plasma sodium levels and increases in potassium levels. Baxdrostat was safe and well tolerated with a half-life that supports once-daily dosing. The dose-dependent reduction in plasma aldosterone and lack of effect on cortisol demonstrate the selective blockade of aldosterone synthase.<\/jats:p>","DOI":"10.1038\/s41440-022-01070-4","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T03:03:58Z","timestamp":1666235038000},"page":"108-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers"],"prefix":"10.1038","volume":"46","author":[{"given":"Mason W.","family":"Freeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Isaacsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"1070_CR1","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127\u2013248.","journal-title":"J Am Coll Cardiol"},{"key":"1070_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486\u201392.","journal-title":"Nat Clin Pract Nephrol"},{"key":"1070_CR3","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"1070_CR4","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","volume":"24","author":"MS Kallistratos","year":"2018","unstructured":"Kallistratos MS, Pittaras A, Theodoulidis I, Grassos C, Poulimenos LE, Manolis AJ. Adverse effects of mineralocorticoid receptor antagonist administration. Curr Pharm Des. 2018;24:5537\u201341.","journal-title":"Curr Pharm Des"},{"key":"1070_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/EJE-12-0631","volume":"168","author":"V Fourkiotis","year":"2013","unstructured":"Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S, et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol. 2013;168:75\u201381.","journal-title":"Eur J Endocrinol"},{"key":"1070_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/014107680109400803","volume":"94","author":"M Epstein","year":"2001","unstructured":"Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med. 2001;94:378\u201383.","journal-title":"J R Soc Med"},{"key":"1070_CR7","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K Swedberg","year":"1990","unstructured":"Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730\u20136.","journal-title":"Circulation"},{"key":"1070_CR8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1053\/euhj.1998.1093","volume":"19","author":"P Vantrimpont","year":"1998","unstructured":"Vantrimpont P, Rouleau JL, Ciampi A, Harel F, de Champlain J, Bichet D, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J. 1998;19:1552\u201363.","journal-title":"Eur Heart J"},{"key":"1070_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","volume":"25","author":"R Latini","year":"2004","unstructured":"Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25:292\u20139.","journal-title":"Eur Heart J"},{"key":"1070_CR10","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","volume":"115","author":"G Guder","year":"2007","unstructured":"Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754\u201361.","journal-title":"Circulation"},{"key":"1070_CR11","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","volume":"114","author":"F Beygui","year":"2006","unstructured":"Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthelemy O, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114:2604\u201310.","journal-title":"Circulation"},{"key":"1070_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/eurheartj\/ehr176","volume":"33","author":"F Ivanes","year":"2012","unstructured":"Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautiere K, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33:191\u2013202.","journal-title":"Eur Heart J"},{"key":"1070_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1042\/CS20070123","volume":"113","author":"AM Marney","year":"2007","unstructured":"Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci. 2007;113:267\u201378.","journal-title":"Clin Sci"},{"key":"1070_CR14","doi-asserted-by":"publisher","first-page":"8054","DOI":"10.1021\/acs.jmedchem.5b00851","volume":"58","author":"RE Martin","year":"2015","unstructured":"Martin RE, Aebi JD, Hornsperger B, Krebs HJ, Kuhn B, Kuglstatter A, et al. Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors: in vivo evaluation in rodents and cynomolgus monkeys. J Med Chem. 2015;58:8054\u201365.","journal-title":"J Med Chem"},{"key":"1070_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","volume":"69","author":"K Bogman","year":"2017","unstructured":"Bogman K, Schwab D, Delporte ML, Palermo G, Amrein K, Mohr S, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69:189\u201396.","journal-title":"Hypertension"},{"key":"1070_CR16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"L Amar","year":"2010","unstructured":"Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010;56:831\u20138.","journal-title":"Hypertension"},{"key":"1070_CR17","doi-asserted-by":"publisher","first-page":"147032031771788","DOI":"10.1177\/1470320317717883","volume":"18","author":"J Sloan-Lancaster","year":"2017","unstructured":"Sloan-Lancaster J, Raddad E, Flynt A, Jin Y, Voelker J, Miller JW. LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase. J Renin Angiotensin Aldosterone Syst. 2017;18:1470320317717883.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"1070_CR18","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1023\/A:1026451721686","volume":"17","author":"BP Smith","year":"2000","unstructured":"Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17:1278\u201383.","journal-title":"Pharm Res"},{"key":"1070_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/pst.326","volume":"8","author":"J Hummel","year":"2009","unstructured":"Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 2009;8:38\u201349.","journal-title":"Pharm Stat"},{"key":"1070_CR20","doi-asserted-by":"publisher","first-page":"20961","DOI":"10.1016\/S0021-9258(19)30030-4","volume":"264","author":"E Mornet","year":"1989","unstructured":"Mornet E, Dupont J, Vitek A, White PC. Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem. 1989;264:20961\u20137.","journal-title":"J Biol Chem"},{"key":"1070_CR21","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJM199610173351607","volume":"335","author":"W Oelkers","year":"1996","unstructured":"Oelkers W. Adrenal insufficiency. N Engl J Med. 1996;335:1206\u201312.","journal-title":"N Engl J Med"},{"key":"1070_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/00000542-198412000-00003","volume":"61","author":"RL Wagner","year":"1984","unstructured":"Wagner RL, White PF. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology. 1984;61:647\u201351.","journal-title":"Anesthesiology"},{"key":"1070_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0340-9","volume":"12","author":"J Menard","year":"2014","unstructured":"Menard J, Rigel DF, Watson C, Jeng AY, Fu F, Beil M, et al. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects. J Transl Med. 2014;12:340.","journal-title":"J Transl Med"},{"key":"1070_CR24","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1097\/HJH.0b013e328363570c","volume":"31","author":"CD Schumacher","year":"2013","unstructured":"Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013;31:2085\u201393.","journal-title":"J Hypertens"},{"key":"1070_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pharmthera.2015.07.006","volume":"154","author":"J Deinum","year":"2015","unstructured":"Deinum J, Riksen NP, Lenders JW. Pharmacological treatment of aldosterone excess. Pharm Ther. 2015;154:120\u201333.","journal-title":"Pharm Ther"},{"key":"1070_CR26","doi-asserted-by":"crossref","first-page":"204800401452244","DOI":"10.1177\/2048004014522440","volume":"3","author":"M Hargovan","year":"2014","unstructured":"Hargovan M, Ferro A. Aldosterone synthase inhibitors in hypertension: current status and future possibilities. JRSM Cardiovasc Dis. 2014;3:2048004014522440.","journal-title":"JRSM Cardiovasc Dis"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01070-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01070-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01070-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T05:03:54Z","timestamp":1674018234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01070-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1070"],"URL":"https:\/\/doi.org\/10.1038\/s41440-022-01070-4","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MF is an employee of CinCor Pharma, Inc. and receives stock-based compensation. JH is an employee of CinCor Pharma, Inc. and receives stock-based compensation. MB is an employee of and has equity in CinRx Pharma, LLC, which has an equity stake in CinCor Pharma, Inc. BM is an employee of and has equity in CinRx Pharma, LLC, which has an equity stake in CinCor Pharma, Inc. JI is an employee of and has equity in CinRx Pharma, LLC, which has an equity stake in CinCor Pharma, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonization. The study was conducted at Medpace Clinical Pharmacology Unit (Cincinnati, OH), with approval from the institutional review board, and all patients provided written informed consent before enrollment in the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}